News
Australia Builds a New Radiopharmaceutical Gateway from Research to Patient Care
2+ day, 2+ hour ago (102+ words) 17 July 2026 | Friday | News Radiopharmaceuticals that can reveal the location of tumors on scans and deliver therapeutic radiation directly to cancer cells are rapidly emerging as the 'sixth pillar' of cancer care, alongside surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy. TMSNM…...
Harbour BioMed, Kelun-Biotech Secure China IND Approval for Bispecific Antibody in Asthma
2+ day, 1+ hour ago (297+ words) BioPharma APAC - Harbour BioMed, Kelun-Biotech Secure China IND Approval for Bispecific Antibody in Asthma 17 July 2026 | Friday | News Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas,…...
Evonik and evitria Simplify CHO-Based Protein Production with Ready-to-Use Expression Kit
2+ day, 2+ hour ago (143+ words) 17 July 2026 | Friday | News “By combining evitria’s proven capabilities with our extensive biopharma experience, we are connecting our customers with best-in-class protein expression solutions. Our goal is to simplify processes, enable faster biologics development, and therefore further strengthen our position in…...
Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence
2+ day, 10+ hour ago (361+ words) 16 July 2026 | Thursday | Analysis REPORTAGE / PLASMA SUPPLY That bottle is our unit. Everything that follows happens to it. The unit is carried to the back of the centre, and here it meets the first machine that could kill it. The alarm…...
From Capacity to Capability: The New Race to Lead ASEAN Biomanufacturing
2+ day, 9+ hour ago (524+ words) 16 July 2026 | Thursday | Expert Insight ASEAN is entering a new phase of biopharmaceutical manufacturing, where simply building more capacity will no longer guarantee competitiveness. As product pipelines become more complex and demand increasingly unpredictable, the advantage is shifting towards manufacturers that…...
Telix Takes Next-Generation PSMA Radioligand Therapy into Earlier Prostate Cancer Treatment
2+ day, 16+ hour ago (526+ words) BioPharma APAC - Telix Takes Next-Generation PSMA Radioligand Therapy into Earlier Prostate Cancer Treatment 16 July 2026 | Thursday | News - First patients dosed in OPTIMAL-e[1] Phase 2 study evaluating TLX597-Tx for metastatic hormone-sensitive prostate cancer at St Vincent's Hospital Sydney. - OPTIMAL-e will evaluate TLX597-Tx in…...
Metabolon Expands Microbiome Panel to Screen Over 800 Metabolites
2+ day, 22+ hour ago (676+ words) BioPharma APAC - Metabolon Expands Microbiome Panel to Screen Over 800 Metabolites 16 July 2026 | Thursday | News Enhanced panel screens for more than 800 microbiome-associated metabolites, giving researchers a broader view of microbial activity linked to human health, nutrition, disease, and treatment response Metabolon, Inc.,…...
Insilico Medicine, Bora Pharmaceuticals Forge $2.5B Alliance to Build AI-Driven Drug Innovation Model
3+ day, 3+ hour ago (986+ words) BioPharma APAC - Insilico Medicine, Bora Pharmaceuticals Forge $2.5B Alliance to Build AI-Driven Drug Innovation Model 16 July 2026 | Thursday | News Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model Insilico Medicine…...
China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?
3+ day, 15+ hour ago (618+ words) 15 July 2026 | Wednesday | Analysis THE RESHUFFLE · ANALYSIS Every hub in the region has an answer ready. The harder question is whether the answer is capacity that exists, capacity that is announced, or capacity that is merely hoped for. Those are three…...
Q32 Bio Reports Positive Phase 2a Results for Bempikibart in Severe Alopecia Areata, Plans Pivotal Programme
4+ day, 8+ hour ago (280+ words) 15 July 2026 | Wednesday | News -- Clinically meaningful efficacy data on the primary endpoint was observed with a mean percent reduction in SALT score from baseline of 35.3% in the prespecified mITT analysis -- -- 40.0% of patients achieved SALT-20 response at Week 36 in the mITT analysis…...